ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer

Katriina J. Peltola; Petri Bono; Robert  Hugh Jones; Egils Vjaters; Pirjo  Nykänen; Annamari Vuorela; Riikka Oksala; Pasi Pohjanjousi; Mika V. J. Mustonen; Karim Fizazi; Christophe Massard

doi:10.1016/j.euf.2018.08.022

ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer

Katriina J. Peltola, Petri Bono, Robert Hugh Jones, Egils Vjaters, Pirjo Nykänen, Annamari Vuorela, Riikka Oksala, Pasi Pohjanjousi, Mika V. J. Mustonen , Karim Fizazi, Christophe Massard

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	European Urology Focus
Volume	6
Issue number	1
Pages (from-to)	63-70
Number of pages	8
ISSN	2405-4569
DOIs	https://doi.org/10.1016/j.euf.2018.08.022
Publication status	Published - 15 Jan 2020
MoE publication type	A1 Journal article-refereed

Fields of Science

3122 Cancers
3126 Surgery, anesthesiology, intensive care, radiology
Androgen receptor
Castration-resistant prostate cancer
CYP17A1
ODM-204
Phase I clinical trial
ABIRATERONE
GENE
AMPLIFICATION
PROGRESSION

Access to Document

10.1016/j.euf.2018.08.022

1-s2.0-S2405456918302414-mainFinal published version, 1.08 MBLicence: CC BY-NC-ND

Cite this

Peltola, K. J., Bono, P., Hugh Jones, R., Vjaters, E., Nykänen, P., Vuorela, A., Oksala, R., Pohjanjousi, P., Mustonen , M. V. J., Fizazi, K., & Massard, C. (2020). ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer. European Urology Focus, 6(1), 63-70. https://doi.org/10.1016/j.euf.2018.08.022

@article{12b88df699aa491cb7d9059e4a0fac3f,

title = "ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer",

keywords = "3122 Cancers, 3126 Surgery, anesthesiology, intensive care, radiology, Androgen receptor, Castration-resistant prostate cancer, CYP17A1, ODM-204, Phase I clinical trial, ABIRATERONE, GENE, AMPLIFICATION, PROGRESSION",

author = "Peltola, {Katriina J.} and Petri Bono and {Hugh Jones}, Robert and Egils Vjaters and Pirjo Nyk{\"a}nen and Annamari Vuorela and Riikka Oksala and Pasi Pohjanjousi and Mustonen, {Mika V. J.} and Karim Fizazi and Christophe Massard",

year = "2020",

month = jan,

day = "15",

doi = "10.1016/j.euf.2018.08.022",

language = "English",

volume = "6",

pages = "63--70",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier Science B.V.",

number = "1",

}

Peltola, KJ , Bono, P, Hugh Jones, R, Vjaters, E, Nykänen, P, Vuorela, A, Oksala, R, Pohjanjousi, P, Mustonen , MVJ, Fizazi, K & Massard, C 2020, 'ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer', European Urology Focus, vol. 6, no. 1, pp. 63-70. https://doi.org/10.1016/j.euf.2018.08.022

TY - JOUR

T1 - ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer

AU - Peltola, Katriina J.

AU - Bono, Petri

AU - Hugh Jones, Robert

AU - Vjaters, Egils

AU - Nykänen, Pirjo

AU - Vuorela, Annamari

AU - Oksala, Riikka

AU - Pohjanjousi, Pasi

AU - Mustonen , Mika V. J.

AU - Fizazi, Karim

AU - Massard, Christophe

PY - 2020/1/15

Y1 - 2020/1/15

KW - 3122 Cancers

KW - 3126 Surgery, anesthesiology, intensive care, radiology

KW - Androgen receptor

KW - Castration-resistant prostate cancer

KW - CYP17A1

KW - ODM-204

KW - Phase I clinical trial

KW - ABIRATERONE

KW - GENE

KW - AMPLIFICATION

KW - PROGRESSION

U2 - 10.1016/j.euf.2018.08.022

DO - 10.1016/j.euf.2018.08.022

M3 - Article

SN - 2405-4569

VL - 6

SP - 63

EP - 70

JO - European Urology Focus

JF - European Urology Focus

IS - 1

ER -